Abstract
The integration of imaging characteristics and genomic data has started a new trend in approach toward management of glioblastoma (GBM). Many ongoing studies are investigating imaging phenotypical signatures that could explain more about the behavior of GBM and its outcome. The discovery of biomarkers has played an adjuvant role in treating and predicting the outcome of patients with GBM. Discovering these imaging phenotypical signatures and dysregulated pathways/genes is needed and required to engineer treatment based on specific GBM manifestations. Characterizing these parameters will establish well-defined criteria so researchers can build on the treatment of GBM through personal medicine.
Original language | English (US) |
---|---|
Pages (from-to) | 731-740 |
Number of pages | 10 |
Journal | Magnetic resonance imaging clinics of North America |
Volume | 24 |
Issue number | 4 |
DOIs | |
State | Published - Nov 1 2016 |
Keywords
- Genomics
- Glioblastoma
- Imaging
- Outcome
- Prognosis
- Survival
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging